Rani Therapeutics Hldgs (RANI) closed at $0.61 on October 27, 2026, down 1.2% from the previous close, on volume of 312,386 shares (30-day average 570,632).
Data as of October 27, 2026.
27-Oct-2026
Rani Therapeutics to Participate in the Chardan Healthcare Conference
Globe Newswire (Tue, 13-Oct 4:05 PM ET)
Rani Therapeutics Announces Acceptance into U.S. FDA's Emerging Technology Program (ETP)
Globe Newswire (Mon, 5-Oct 8:00 AM ET)
Rani Therapeutics to Participate in Upcoming September Conferences
Globe Newswire (Tue, 8-Sep 8:00 AM ET)
Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update
Globe Newswire (Thu, 13-Aug 4:05 PM ET)
Rani Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
Globe Newswire (Mon, 10-Aug 8:00 AM ET)
Rani Therapeutics Appoints Michelle Gilson to Board of Directors
Globe Newswire (Tue, 4-Aug 8:00 AM ET)
Market Chameleon (Mon, 20-Oct 6:34 AM ET)
Market Chameleon (Fri, 17-Oct 5:52 AM ET)
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
Rani Therapeutics Hldgs trades on the NASDAQ stock market under the symbol RANI.
As of October 27, 2026, RANI stock price declined to $0.61 with 312,386 million shares trading.
RANI has a beta of 4.13, meaning it tends to be more sensitive to market movements. RANI has a correlation of 0.10 to the broad based SPY ETF.
RANI has a market cap of $70.33 million. This is considered a Micro Cap stock.
Last quarter Rani Therapeutics Hldgs reported $2 million in Revenue and -$.04 earnings per share. This beat revenue expectation by $628,000 and exceeded earnings estimates by $.01.
In the last 3 years, RANI traded as high as $8.75 and as low as $.39.
The top ETF exchange traded funds that RANI belongs to (by Net Assets): VTI, VXF, IBBQ, BIB.
RANI has underperformed the market in the last year with a price return of -66.5% while the SPY ETF gained +14.8%. RANI has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -28.4% and -18.9%, respectively, while the SPY returned +4.4% and -1.1%, respectively.
RANI support price is $.59 and resistance is $.65 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RANI shares will trade within this expected range on the day.
